CC
ALPN

Corton Capital’s Alpine Immune Sciences Inc ALPN Stock Holding History

Corton Capital’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,934
Closed -$323K – 688
2023
Q4 		$323K Buy
+16,934
New +$235K 0.1% 295

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Corton Capital's ALPN Position: Q1 2024 in Review

Corton Capital sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2024, closing a stake of 16,934 shares — an estimated $323K sold.

Corton Capital first reported a position in ALPN in Q4 2023 and held it in 1 quarter. The position peaked at $323K in Q4 2023. 180 funds tracked by Wall St. Rank hold ALPN as of Q1 2024.

  • Corton Capital reported no remaining Alpine Immune Sciences Inc position as of Q1 2024 after selling out during the quarter.
  • Corton Capital sold 16,934 Alpine Immune Sciences Inc shares in Q1 2024, an estimated $323K.
  • Corton Capital first reported a position in Alpine Immune Sciences Inc in Q4 2023 and held it in 1 quarter.
  • Corton Capital's Alpine Immune Sciences Inc position peaked at $323K in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2024.

Based on Corton Capital's 13F filing for Q1 2024, filed 15 May 2024.